文献速递关节外科

氨甲环酸联合利伐沙班血栓预防减少初次非骨水泥全髋关节置换术后失血的随机双盲安慰剂对照试验

A randomized, double-blind, placebo-controlled trial on the efficacy of tranexamic acid combined with rivaroxaban thromboprophylaxis in reducing blood loss after primary cementless total hip arthroplasty.
PubMed 文献 · Bone Joint J · 2019-01-01

这项多中心前瞻性随机双盲安慰剂对照试验纳入229例后路初次非骨水泥全髋关节置换术患者,比较短程与长程静脉氨甲环酸方案对比安慰剂减少围手术期真实失血的效果。氨甲环酸较安慰剂显著减少失血(p<0.001),短程与长程方案间非劣效性成立(p=0.027),未报告血栓栓塞并发症。

要点

  • 短程和长程静脉氨甲环酸均较安慰剂显著减少围手术期真实失血(p<0.001)。
  • 短程与长程方案比较的非劣效性成立(p=0.027)。
  • 未报告静脉或动脉血栓栓塞并发症。

核心结论

  • 在后路初次非骨水泥全髋关节置换术并接受利伐沙班血栓预防的患者中,短程和长程静脉氨甲环酸方案较安慰剂显著减少围手术期真实失血,且无血栓栓塞并发症。
  • 二次分析支持短程方案对比长程方案在减少围手术期真实失血方面的非劣效性。

研究设计与样本

  • 多中心、前瞻性、随机、双盲、安慰剂对照试验,纳入229例后路初次非骨水泥全髋关节置换术患者。
  • 患者中98例男性、131例女性,平均年龄65.5岁(范围32至91岁)。
  • 利伐沙班延长血栓预防自手术当日开始。
  • 主要结局为术后72小时评估的围手术期真实失血。

主要发现

  • 氨甲环酸较安慰剂显著减少围手术期失血(p<0.001)。
  • 短程氨甲环酸组与安慰剂组平均差异为525.3 ml。
  • 长程氨甲环酸组与安慰剂组平均差异为550.1 ml。
  • 未报告静脉或动脉血栓栓塞并发症。
  • 短程与长程方案比较时,95%置信区间上限低于预设非劣效性界值(p=0.027)。

关键数值与推荐

  • 主要结局为术后72小时评估的围手术期真实失血(基线至术后第3天)。
  • 短程氨甲环酸方案为3小时内两剂静脉给药。
  • 长程氨甲环酸方案为11小时内四剂静脉给药。
  • 非劣效性比较的预设界值原文未写明。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Cementless primary total hip arthroplasty (THA) is associated with risks of bleeding and thromboembolism. Anticoagulants are effective as venous thromboprophylaxis, but with an increased risk of bleeding. Tranexamic acid (TXA) is an efficient antifibrinolytic agent, but the mode and timing of its administration remain controversial. This study aimed to determine whether two intravenous (IV) TXA regimens (a three-hour two-dose (short-TXA) and 11-hour four-dose (long-TXA)) were more effective than placebo in reducing perioperative real blood loss (RBL, between baseline and day 3 postoperatively) in patients undergoing THA who receive rivaroxaban as thromboprophylaxis. The secondary aim was to assess the non-inferiority of the reduction of blood loss of the short protocol versus the long protocol. PATIENTS AND METHODS: A multicentre, prospective, randomized, double-blind, placebo-controlled trial was undertaken involving 229 patients undergoing primary cementless THA using a posterior approach, whose extended rivaroxaban thromboprophylaxis started on the day of surgery. There were 98 male and 131 female patients, with a mean age of 65.5 years (32 to 91). The primary outcome, perioperative RBL, was evaluated at 72 hours postoperatively. The efficacy of short- and long-TXA protocols in the reduction of perioperative RBL was compared with a placebo group. RESULTS: TXA significantly reduced perioperative blood loss compared with placebo (p < 0.001); the mean differences were 525.3 ml (short-TXA vs placebo) and 550.1 ml (long-TXA vs placebo). No venous or arterial thromboembolic complications were reported. The upper boundary of the 95% confidence interval, when comparing short and long protocols, was below the pre-specified margin of non-inferiority (p = 0.027). CONCLUSION: In patients undergoing primary cementless THA, using a posterior approach, who are treated with rivaroxaban for thromboembolic prophylaxis, short- and long-TXA IV protocols are significantly more effective than placebo in reducing perioperative RBL, without any thromboembolic complications. Non-inferiority of a short- versus a long-TXA protocol in reducing perioperative RBL was supported in a secondary analysis.

来源:Bone Joint J,查看原文。版权归原作者所有。

引用

  1. Clavé A, Gérard R, Lacroix J, et al. A randomized, double-blind, placebo-controlled trial on the efficacy of tranexamic acid combined with rivaroxaban thromboprophylaxis in reducing blood loss after primary cementless total hip arthroplasty. Bone Joint J. 2019. PMID: 30700116. doi:10.1302/0301-620X.101B2.BJJ-2018-0898.R1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。